Your hub to the latest Knowledge in Nuclear Medicine/Molecular Imaging
Press releases
World's leading hospitals leverage Hermia® for advanced molecular imaging
In a testament to its global impact, the top hospitals recognized in Newsweek's World's Best Hospitals 2025 rankings have integrated Hermia, the all-in-one molecular imaging software suite from Hermes Medical Solutions, into their clinical practices. From leading institutions in the United States and to premier hospitals in Europe and beyond, Hermia has become an essential tool in delivering precise diagnostics and optimized patient care.
Hermia will be available on booths of Canon, Siemens and Spectrum Dynamics at RSNA 2024
Hermes Medical Solutions (HMS), a leader in molecular imaging software development will demonstrate its true vendor-neutral character through partnerships at this year’s RSNA to provide customers of Canon Medical Systems, Siemens Healthineers and Spectrum Dynamics Medical with access to the Hermia software.
Hermes Medical Solutions Receives 510(k) FDA Clearance for its Hermia NM Processing (Hybrid Viewer)
Hermes Medical Solutions (HMS), global market leader in molecular imaging and dosimetry software solutions receives 510(k) FDA Clearance for its Hybrid Viewer 7.0. The product has previously been CE-marked and holds a medical device license from Health Canada.
Scientific publications
Biodistribution and dosimetry of [Lu-177]Lu‐SibuDAB in patients with metastatic castration‐resistant prostate cancer
Several prostate-specific membrane antigen (PSMA) radiopharmaceuticals have been used for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). In an attempt to improve the tumour accumulation, new PSMA ligands were developed with an albumin-binding entity to enhance the blood circulation and, hence, tumour accumulation. In preclinical studies, [Lu-177]Lu-SibuDAB, a radiopharmaceutical with moderate albumin-binding properties, outperformed [177Lu]Lu-PSMA-617 and [Lu-177]Lu-PSMA-I&T. The aim of this study was to evaluate the dosimetry of [Lu-177]Lu-SibuDAB in patients diagnosed mCRPC.
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
Bone marrow toxicity in advanced prostate cancer patients who receive [Lu-177]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) patients, prevention of late bone marrow toxicity is even more crucial due to longer life expectancy. To date, bone marrow dosimetry is primarily performed using blood sampling. This method is time consuming and does not account for possible active bone marrow uptake. Therefore other methodologies are investigated. We calculated the bone marrow absorbed dose for [Lu-177]Lu-PSMA-617 in mHSPC patients using SPECT/CT imaging and compared it to the blood sampling method as reference.
Internal dosimetry study of [Rb-82]Cl using a long axial field-of-view PET/CT
Our study suggests that the radiation dose associated with [Rb-82]Cl PET/CT can be assessed by means of dynamic LAFOV PET and that it is lower compared to literature values.
Brochures
Theranostics Brochure
Brochure dedicated to the advanced tools for Theranostics and Therapies within the Hermia software.
Hermia product overview
Product overview of Hermia, a state-of-the-art software suite that supports all clinical scenarios in NM/MI on all cameras.
Future Liver Remnant Function
Ensure the best outcome for your patients undergoing major liver resection
White papers
Hermia SPECT Reconstruction
The quality of SPECT imaging is reduced by photon attenuation, resolution loss due to collimator-detector blur, photon scatter, and noise. All these factors limit both the visual quality and quantitative power of SPECT images. Hermia SPECT Reconstruction provides methods to compensate for the effects of the aforementioned four factors by modelling them in iterative reconstruction.
Hermia Advanced Bone SPECT Reconstruction
Our easy-to-use software enables precise determination of reconstruction parameters, and we are proud to be able to offer two Bayesian reconstruction algorithms to optimise your bone SPECT/CT images: AMAP-Smooth and AMAP-RDP.
